From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2007
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 2.32
Pain Relevance 0.10

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (RPS6KB1) aging (RPS6KB1) ribosome (RPS6KB1)
cytoplasm (RPS6KB1) cytosol (RPS6KB1) signal transduction (RPS6KB1)
Anatomy Link Frequency
uterine 1
RPS6KB1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Immobilon 4 92.48 High High
palliative 8 54.68 Quite High
antagonist 20 38.96 Quite Low
Opioid 10 38.52 Quite Low
backache 1 15.72 Low Low
opiate 18 5.00 Very Low Very Low Very Low
mu opioid receptor 10 5.00 Very Low Very Low Very Low
Morphine 6 5.00 Very Low Very Low Very Low
analgesia 4 5.00 Very Low Very Low Very Low
Pain 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 109 98.12 Very High Very High Very High
Disease 48 97.96 Very High Very High Very High
Renal Cancer 31 97.52 Very High Very High Very High
Pancreatic Cancer 37 95.94 Very High Very High Very High
Metastasis 14 87.72 High High
Colorectal Cancer 4 76.88 Quite High
Leiomyosarcoma 18 75.76 Quite High
Epithelioid Leiomyoma 4 74.44 Quite High
Smooth Muscle Tumor 14 67.44 Quite High
Uterine Fibroids 7 61.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The recent demonstration of elevated phospho-p70S6K and reduced phospho-AKT expression, indicative of mTOR (mammalian target of rapamycin) activation, in a group of extra-renal PEComas raises the possibility of using mTOR inhibitors such as rapamycin in the treatment of uterine PEComas and is another argument for their routine segregation [82].
Gene_expression (expression) of p70S6K in uterine
1) Confidence 0.75 Published 2008 Journal Int Semin Surg Oncol Section Body Doc Link PMC2278149 Disease Relevance 0.78 Pain Relevance 0
The phosphoinositide 3-OH kinase (PI3K)/Akt pathway, which is frequently amplified or activated in pancreatic cancer, may also contribute to resistance in several ways including the inhibition of proapoptotic proteins BAD and caspase 9 (Schlieman et al. 2003), dysregulation of the mammalian target of rapamycin (mTOR)-S6K1 signaling pathway (Asano et al. 2005), and activation of the nuclear factor kappa B (NF?
Gene_expression (signaling) of S6K1 associated with pancreatic cancer
2) Confidence 0.46 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012429 Disease Relevance 0.75 Pain Relevance 0
Total protein expression of mTOR and S6K1 kinase was unchanged following the study diets (Figure 2).
Gene_expression (expression) of S6K1
3) Confidence 0.30 Published 2009 Journal Nutr Metab (Lond) Section Body Doc Link PMC2761378 Disease Relevance 0 Pain Relevance 0
Interestingly, the mTOR inhibitor, temsirolimus, did not attenuate Akt activation but inhibited the mTOR Complex 1 target p70 S6K [4] (Figure 4-B).
Gene_expression (target) of S6K
4) Confidence 0.25 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0 Pain Relevance 0
Rabbit anti-pSer473Akt, rabbit anti-pThr308Akt, rabbit anti-Akt, rabbit anti-pThr389 p70 S6K and anti-p70 S6K antibodies were purchased from Cell Signaling Technologies (Danvers, MA).
Gene_expression (antibodies) of S6K
5) Confidence 0.25 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0 Pain Relevance 0.05
A substantial study of 375 patients investigated the prognostic significance of mTOR pathway components in tumors obtained at nephrectomy, and observed adverse prognostic impact on disease-specific survival of pS6K, PTEN and Akt independent of stage.73 A small study further suggested that pS6K and possibly Akt were predictors of response to temsirolimus for advanced RCC.67,74 However an extension of the study20 of temsirolimus for poor prognosis advanced RCC did not find a correlation between PTEN and HIF-1?
Spec (possibly) Gene_expression (possibly) of pS6K associated with cancer, renal cancer and disease
6) Confidence 0.12 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2880340 Disease Relevance 0.79 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools